3 results about "Acute thrombosis" patented technology

The application belongs to the technical field of pharmaceutical preparations, and specifically provides a kind of indobufen freeze-dried oral disintegrating tablet and a preparation method thereof.The freeze-dried oral disintegrating tablet contains indobufen and xanthan gum, and the freeze-dried oral disintegrating tablet can be obtained by freeze-drying technology after the above components are prepared into a suspension.The freeze-dried oral disintegrating tablet provided by the application has the technical characteristics of good properties, complete demolding, high drug loading, good content uniformity, rapid disintegration and rapid dissolution, and can meet the needs of rapid anti-platelet therapy in acute thrombosis events.

This invention provides a multifunctional electrospun material and its application, as well as an artificial blood vessel and its preparation method. The electrospun material includes an electrospun material substrate and deferoxamine. This electrospun material possesses anti-inflammatory, antioxidant, antibacterial, and anticoagulant functions. When applied to the preparation of artificial blood vessels, it can improve the regenerative capacity of blood vessels, especially by protecting vascular cells through inhibiting inflammation and hyperglycemia-induced oxidative stress in diabetic and elderly patients, thereby promoting angiogenesis. The loaded deferoxamine can achieve long-term, slow release according to the environment of the transplantation site. The released deferoxamine can prevent acute thrombosis by inhibiting platelet adhesion and activation, and can also protect the microenvironment of the transplantation site by resisting oxidative stress and inflammation levels, promoting cell infiltration and regeneration, and protecting regenerated cells.

An immunosensor device is disclosed for rapid detection of circulating biomarkers associated with thrombosis, including C-reactive protein (CRP), calprotectin, soluble platelet selectin (sP-selectin), and D-dimer. The immunosensors were fabricated using fiber-laser engraving of carbon nanotubes and CO2-laser cutting of microfluidic channels and features, along with the electrochemical deposition of gold nanoparticles to conjugate with biomarker-specific aptamers and antibody. Using unsupervised clustering based on 4-biomarker concentrations, thrombotic events were predicted in 49 of 53 patients. The 4-biomarker combination yielded an area under the receiver operating characteristic curve (AUC) of 0.95, demonstrating high sensitivity and specificity for acute thrombosis prediction compared to the AUC values for individual biomarker: CRP (0.773), calprotectin (0.711), sP-selectin (0.683), and D-dimer (0.739). The immunosensor device with unsupervised clustering provides accurate and efficient methods for predicting thrombosis, guiding personalized medicine.